Has Dan Lender, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,566,242 in general payments to Dan Lender, MD across 404 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dan Lender, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dan Lender, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dan Lender, MD

Endocrinology, Diabetes & Metabolism · Rockwall, TXNPI 1760445274

Payments from drug & device makers

$2,566,242in general payments, 2019–2025

Across 404 payments — averaging $6352.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$1.9M
Genentech, Inc.$215K
Vertex$170K
Hoffmann-la Roche Limited$74K
F. Hoffmann-la Roche AG$51K
Amgen$29K
plus $103K from 40 others

$73,226in research payments, 2019–2025

Across 6 payments — averaging $12,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$73K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	74	$1,924,896
Genentech, Inc.	20	$214,688
Vertex	3	$169,566
Hoffmann-la Roche Limited	8	$74,112
F. Hoffmann-la Roche AG	9	$51,458
Amgen	3	$28,614
AstraZeneca(2 entities)	13	$26,894
Boehringer Ingelheim International GmbH	21	$24,288
Medtronic(2 entities)	24	$19,339
Shionogi Inc	1	$17,703
Eli Lilly Export S.A. Puerto Rico Branch	1	$7,813
Novo Nordisk	43	$2,183
Novo Nordisk AS	7	$1,538
Mannkind Corporation	30	$519
Dexcom, Inc.	25	$487
Amarin Pharma, Inc.	24	$440
Abbott	14	$258
AbbVie	10	$172
Lilly USA, LLC	11	$162
BD	6	$135
Bayer	5	$85
Boehringer Ingelheim	5	$75
Radius Health, Inc.	4	$65
Smith+Nephew	1	$64
IBSA Pharma Inc.	4	$61
Zealand Pharma US, Inc.	3	$61
Xeris Pharmaceuticals, Inc.	4	$56
Ascensia Diabetes Care US Inc.	3	$53
Pfizer	3	$48
Insulet Corporation	2	$45
Embecta Corp.	2	$45
Amneal Pharmaceuticals LLC	2	$41
Johnson & Johnson	2	$33
Sanofi-aventis U.S. LLC	2	$32
Companion Medical, Inc.	2	$31
Antares Pharma, Inc.	2	$30
Merck	2	$29
Valeritas, Inc.	1	$23
Ultragenyx Pharmaceutical Inc.	1	$21
Nevro Corp.	1	$17
GRT US Holding, Inc.	1	$14
Currax Pharmaceuticals LLC	1	$12
Regeneron Healthcare Solutions, Inc.	1	$12
Acerus Pharmaceuticals Corporation	1	$11
BETA Bionics, Inc.	1	$10
Cequr Corporation	1	$3

How this compares

$2,566,242 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024

$17,946

Medicare patients

Services billed

193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Rockwall

Julio RosenstockDallas$24.9M
Michelle WelchShavano Park$17.3M
Maria CabanillasHouston$16.4M
Sumana GangiMesquite$13.2M
Damaris VegaHouston$12.3M
Mark KipnesSan Antonio$10.3M
Amer Al KaradshehHouston$8.8M
Ildiko LingvayDallas$8.2M
Eduardo LunaEdinburg$7.6M
Thomas BlevinsAustin$7.4M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →